NCT05389215

Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of DWN12088 in Patients With Idiopathic Pulmonary Fibrosis

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 102 (estimated)
• Sponsor: Daewoong Pharmaceutical Co. LTD. · Industry
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.

Detailed description

This is randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.

Conditions

• Idiopathic Pulmonary Fibrosis

Interventions

Type	Name	Description
DRUG	DWN12088	DWN12088 Xmg Tablet (BID)
DRUG	Placebo	Placebo 0mg Tablet (BID)

Timeline

• Start date: 2022-07-29
• Primary completion: 2026-10-13
• Completion: 2027-01-30
• First posted: 2022-05-25
• Last updated: 2025-08-05

Locations

30 sites across 2 countries: United States, South Korea

Regulatory

• FDA-regulated drug study